The acquisition provides immediate revenue and strategic expansion into nephrology and retinal disease, with strong growth visibility. Traders should monitor SYFOVRE® sales trajectory and upcoming FDA submission for prefilled syringe in H1 2026, which could accelerate adoption. The CVR structure aligns incentives and limits near-term dilution, while Biogen’s plan to de-lever by 2027 supports financial stability.
Price Chart
Executive Summary
Biogen announced the acquisition of Apellis Pharmaceuticals for $41 per share in cash, totaling $5.6 billion in upfront equity consideration, plus a contingent value right (CVR) tied to SYFOVRE® sales milestones. The deal adds two FDA-approved complement-targeting therapies—EMPAVELI® and SYFOVRE®—with combined 2025 revenue of $689 million and expected mid-to-high teens growth through 2028, enhancing Biogen’s immunology and nephrology portfolio.
Key Financial Metrics
Key Facts
- Biogen to acquire Apellis for $41 per share in cash, representing an 86% premium to Apellis’s 90-day volume-weighted average price.
- Total upfront equity value is $5.6 billion; additional CVR of up to $4 per share based on SYFOVRE® global net sales milestones ($1.5B and $2B thresholds between 2027–2030, or $2B in 2031).
- EMPAVELI® and SYFOVRE® generated combined net revenue of $689 million in 2025, expected to grow at mid-to-high teens rate at least through 2028.
- Transaction expected to be accretive to Biogen’s non-GAAP EPS starting in 2027 and boost its non-GAAP EPS CAGR through the end of the decade.
- Deal expected to close in Q2 2026, financed via cash and borrowings; Biogen expects to de-lever fully by end of 2027.
Financial Impact
$5.6 billion upfront cash outlay with potential $4 per share CVR payout; adds $689 million in annual revenue with strong growth trajectory
Risk Factors
- Failure to achieve SYFOVRE® sales milestones could result in no CVR payout, reducing deal upside.
- Integration risk and potential disruption to Apellis’s commercial momentum in key rare disease markets.
- Regulatory or antitrust delays could push closing beyond Q2 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265288 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access